ClinicalTrials.gg
CompletedNCT00095134Updated Dec 6, 2011

Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

A Phase 3 interventional study of risperidone in Major Depressive Disorder, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 70 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-12-06.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
630
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.

Enrollment
6th of 52
630 · median 203
Started
2004
the only one that year
Phase 3
23 of 59
5 open now
Registered
3rd of 59
by date

Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 6th largest by enrollment of the 52 interventional ones that give a count, is the only one that started in 2004, is one of 23 in phase 3, and was the 3rd registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Depressive Disorder, Major by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the efficacy and safety of risperidone versus placebo in subjects with Major Depressive Disorder with sub-optimal response to antidepressant therapy.

Read the detailed description

Many patients who suffer from Major Depressive Disorder (MDD) do not benefit or show only partial benefit from current psychotropic therapy. This clinical trial seeks to study the efficacy and safety of adjunctive treatment with risperidone in patients with MDD who failed to adequately respond to standard antidepressant treatment prior to this trial and who prospectively do not respond to adequate treatment with standard antidepressant therapy (SAD).

Patients entering the open label phase of the study will have already taken a commercially available SAD for a minimum of 4 weeks, and provided the dose was optimal, will continue on this dose of SAD throughout the four-week open-label and six-week double-blind phases of the trial.

If the dose in the four weeks prior to entering the study was not optimal (as per standard clinical practice), the dose will be increased to be within the optimal range and continued at that dose through the entire open-label SAD and double-blind phases.

During the double-blind phase, subjects receive an adjunctive dose of risperidone or placebo, once daily, added to their stable dose of SAD. The starting dose of risperidone or placebo is 0.25 mg for the first three days of the double-blind phase, and is increased to 0.5 mg for days 4 through 14. On the 15th day of this phase, the dose is increased to the target dose of 1.0 mg/day. If response to this dose is not optimal by day 29, it is increased to 2.0 mg/day and is maintained for the duration of the 6-week double-blind phase. This dose may be reduced once to 1.0 mg/day, but then must be maintained at that dose for the remainder of the study.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understand and sign the form
  • Age 18-65
  • Healthy on the basis of Physical Exam
  • Treatment with a single antidepressant 4 weeks prior to study start and willingness to maintain on stable dose of the same antidepressant throughout the study
  • Current diagnosis of Major Depressive Disorder
  • Judgement of the clinician that the subject has shown a sub-optimal response to the antidepressant

Exclusion criteria

Exclusion Criteria:

  • Presence of other serious medical illness(es)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
630 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Difference in therapeutic effect of risperidone and placebo as measured by change in depression rating scale (HAM-D) at end of week 4 of the double-blind phase.

Secondary outcomes

  1. Safety will be assessed through reported adverse events and vital signs (weight, blood pressure, pulse, and temperature).

07

Study locations

70 sites
  • Innovative Clinical Trials, LLC
    Birmingham, Alabama 35205, United States
  • Greystone Medical Research
    Birmingham, Alabama 35242, United States
  • Scottsdale Family Health
    Scottsdale, Arizona 85251, United States
  • Sun Valley Medical
    Sun City, Arizona 85351, United States
  • Southwest Biomedical Research Foundation
    Tucson, Arizona 85711, United States
  • Southwestern Research Institute
    Burbank, California 91506, United States
  • Chrishard Clinical Research
    Inglewood, California 90301, United States
  • Optimum Health Services
    La Mesa, California 91942, United States
  • Pacific Insititute for Medical Research
    Los Angeles, California 90024, United States
  • Optimum Health Services
    Oceanside, California 92056, United States
  • Behavioral Health 2000, LLC
    Riverside, California 92506, United States
  • nTouch Research
    San Diego, California 92103, United States
  • Psychiatric Medicine Center
    New London, Connecticut 06320, United States
  • Glasgow Family Practice
    Newark, Delaware 19702, United States
  • Leonard Bass, MD, PA
    Ft. Lauderdale, Florida 33311, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Roger Miller, MD
    Jacksonville, Florida 32257, United States
  • BioQuan Research Group, Inc.
    North Miami, Florida 33161, United States
  • Family Practice - St. Cloud
    St. Cloud, Florida 34769, United States
  • Allan B. Aven, MD
    Arlington Heights, Illinois 60005, United States
  • nTouch Research - Chicago
    Naperville, Illinois 60542, United States
  • nTouch Research - Peoria
    Peoria, Illinois 61602, United States
  • Balanced Health Research Center
    Peoria, Illinois 61614, United States
  • American Health Network
    Avon, Indiana 46123, United States
  • Research Solutions - Evansville
    Evansville, Indiana 47714, United States
  • Amy Kaissar, MD
    Indianapolis, Indiana 46260, United States
  • Clinco
    Terre Haute, Indiana 47802, United States
  • Hartford Research Group
    Florence, Kentucky 41042, United States
  • New Orleans Medical Institute
    Metairie, Louisiana 70001, United States
  • Brentwood Research Institute
    Shreveport, Louisiana 71101, United States
  • Professional Clinical Research at Great Lakes Family Care
    Cadillac, Michigan 49601, United States
  • Sam Hawatmeh, MD, PC
    St. Louis, Missouri 63125, United States
  • Alliance Medical Center, PC
    Alliance, Nebraska 69301, United States
  • Clinical Trial Associates
    Glendora, New Jersey 08029, United States
  • Partners in Primary Care
    Turnersville, New Jersey 08012, United States
  • ABQ Med., P.C.
    Albuquerque, New Mexico 81709, United States
  • Eastside Comprehensive Medical Services, LLC
    New York, New York 10021, United States
  • Raleigh Medical Group
    Raleigh, North Carolina 27609, United States
  • Salem Research Group
    Winston Salem, North Carolina 27103, United States
  • Community Health Care, Inc.
    Canal Fulton, Ohio 44614, United States
  • Community Research Management Associates, Inc.
    Cincinnati, Ohio 45219, United States
  • Hightop Medical Research Center
    Cincinnati, Ohio 45224, United States
  • CFP Research, Inc.
    Cincinnati, Ohio 45242, United States
  • Martin Schear, MD
    Dayton, Ohio 45406, United States
  • Family Practice Center of Wadsworth
    Wadsworth, Ohio 44281, United States
  • Sooner Clinical Research
    Edmond, Oklahoma 73013, United States
  • Med-line Research
    Moore, Oklahoma 73160, United States
  • Cutting Edge Research Group
    Oklahoma City, Oklahoma 73120, United States
  • Advanced Clinical Trials
    Eugene, Oregon 97401, United States
  • Clinical Research Consultants/Providence Medical
    Medford, Oregon 97504, United States
  • Medford Medical Clinic, LLP
    Medford, Oregon 97504, United States
  • Gateway Medical
    Downingtown, Pennsylvania 19335, United States
  • Feasterville Family Health Care
    Feasterville, Pennsylvania 19053, United States
  • Detweiler Family Medicine
    Lansdale, Pennsylvania 19446, United States
  • Green & Seidner Family Practice
    Lansdale, Pennsylvania 19466, United States
  • Woodburne Family Practice
    Levittown, Pennsylvania 19057, United States
  • Pearl Clinical Research
    Norristown, Pennsylvania 19401, United States
  • Joseph Rybicki, MD
    Philadelphia, Pennsylvania 19152, United States
  • Clinical Trials Research Services, LLC
    Pittsburgh, Pennsylvania 15206, United States
  • Consolidated Clinical Trials, Inc.
    Pittsburgh, Pennsylvania 15221, United States
  • Charles Buttz, MD
    Pottstown, Pennsylvania 19465, United States
  • Research Across America
    Reading, Pennsylvania 19606, United States
  • The Family Practice
    Greer, South Carolina 29651, United States
  • Harmony Clinical Research
    Johnson City, Tennessee 37601, United States
  • DiscoveResearch, Inc.
    Beaumont, Texas 77701, United States
  • South Texas Applied Research
    Corpus Christi, Texas 78411, United States
  • International Clinical Research Associates, LLC
    Richmond, Virginia 23294, United States
  • International Clinical Research Associates
    Virgina Beach, Virginia 23452, United States
  • Richard Neiman, MD
    Kirkland, Washington 98034, United States
  • Daniel Blizzard, MD
    Spokane, Washington 99216, United States
08

References and documents

Publications

  • Pandina G, Turkoz I, Bossie C. Impact of self-reported juvenile abuse on treatment outcome in patients with major depressive disorder. J Affect Disord. 2013 Oct;151(1):384-91. doi: 10.1016/j.jad.2013.01.053. Epub 2013 Jul 10. PubMed 23849714 ↗
  • Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007 Nov 6;147(9):593-602. doi: 10.7326/0003-4819-147-9-200711060-00003. PubMed 17975181 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004 and a completion of Nov 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2004
First posted
Nov 1, 2004
Start
Oct 2004
CompletionActual
Nov 2005
Last update
Dec 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00095134
Collaborators
Janssen, LP
First posted
Nov 1, 2004
Start date
Oct 2004
Completion
Nov 2005
Last update
Dec 6, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion